URGN vs APPN Comparison

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.

Appian Corp is an enterprise software company whose platform unifies process orchestration, artificial intelligence, and data for automating complex business operations. Its platform combines low-code application development, process automation and process mining, AI agents, and a data fabric that connects information across an organization's existing systems without replicating it. The company also provides maintenance and support as well as consulting services and training related to its platform. The majority of its revenue is subscription-based, with the remainder coming from services, and much of that subscription revenue comes from its cloud-based platform. Geographically, the company derives maximum revenue from its Domestic operations and also has a presence internationally.